Results 21 to 30 of about 35,907 (256)

Treatment of women with BRCA mutation

Climacteric, 2023
The cumulative risk for breast and ovarian cancer is high in BRCA1 or BRCA2 mutation carriers. The lifetime risk of breast cancer by the age of 80 years is respectively up to 72% and 69% in BRCA1 and BRCA2 mutation carriers. The risk of ovarian cancer is higher (44%) in BRCA1 than in BRCA2 (17%) mutation carriers.
openaire   +2 more sources

Pancreatic Cancer: Beyond Brca Mutations

Journal of Personalized Medicine, 2022
Pancreatic cancer is the fourth-leading cause of cancer-related deaths worldwide. The outcomes in patients with pancreatic cancer remain unsatisfactory. In the current review, we summarize the genetic and epigenetic architecture of metastatic pancreatic cancer beyond the BRCA mutations, focusing on the genetic alterations and the molecular pathology in
Vincenzo Ricci, Teresa Fabozzi, Maria Anna Bareschino, Emiddio Barletta, Domenico Germano, Immacolata Paciolla, Vincenza Tinessa, Antonio Maria Grimaldi   +7 more
openaire   +2 more sources

Pathological features of BRCA-mutated breast cancer in Shenzhen, China: a single-center study [PDF]

PeerJ
Background Most studies on breast cancer susceptibility gene (BRCA) mutations have focused on Caucasian populations in Europe and North America. Currently, there is a lack of literature and data research in related fields in Shenzhen, China, and even in ...
Jiayu Guan, Sihang Lin, Yanjia Liu, Wenbin Zhou   +3 more
doaj   +2 more sources

Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions

Frontiers in Genetics, 2021
Background:Expert consensus on BRCA1/2 genetic testing and clinical application in Chinese breast cancer patients recommends that BRCA1/2 testing should be performed in those with clinical risk factors, such as an early onset, triple-negative breast ...
Yifan Su, Yifan Su, Yifan Su, Qianlan Yao, Qianlan Yao, Qianlan Yao, Yuyin Xu, Yuyin Xu, Yuyin Xu, Chengli Yu, Chengli Yu, Chengli Yu, Jing Zhang, Jing Zhang, Jing Zhang, Qian Wang, Qian Wang, Qian Wang, Jiwei Li, Jiwei Li, Jiwei Li, Di Shi, Di Shi, Di Shi, Baohua Yu, Baohua Yu, Baohua Yu, Yupeng Zeng, Yupeng Zeng, Yupeng Zeng, Xiaoli Zhu, Xiaoli Zhu, Xiaoli Zhu, Qianming Bai, Qianming Bai, Qianming Bai, Xiaoyan Zhou, Xiaoyan Zhou, Xiaoyan Zhou   +38 more
doaj   +1 more source

BRCA mutations and childhood cancer [PDF]

Cancer Biology & Therapy, 2006
Commentary to:Childhood Cancer in Families with and without BRCA1 or BRCA2 Mutations Ascertained at a High-Risk Breast Cancer ClinicGabriel A. Brooks, Jill E. Stopfer, Julie Erlichman, Rebecca Davidson, Katherine L.
openaire   +2 more sources

BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees

Cancer Biology & Medicine, 2021
Objective: As prostate cancer (PrC) shows a BRCA mutation rate as high as 30%, it becomes crucial to find the optimal selection criteria for genetic testing.
Laura Cortesi, Federica Domati, Annalisa Guida, Isabella Marchi, Angela Toss, Elena Barbieri, Luigi Marcheselli, Marta Venturelli, Simonetta Piana, Claudia Cirilli, Massimo Federico   +10 more
doaj   +1 more source

Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) [PDF]

, 2003
INTRODUCTION: Ancestral mutations in BRCA1 and BRCA2 are common in people of Ashkenazi Jewish descent and are associated with a substantially increased risk of breast and ovarian cancer.
Ellen Solomon, Fisher, S A, Lewis, C M; id_orcid, Lewis, CM, Southey, MC, John L Hopper, Hodgson, SV, Venter, DJ, Michael Friedlander, Hopper, JL, Hopper, J L, Solomon, E, Bankier, A, Hooper, J L, Cathryn M Lewis, Tucker, K, Melissa C Southey, Southey, M C, Lesley Andrews, Friedlander, M, Carmel Apicella, Hodgson, S V, Fisher, SA, Katherine Tucker, Venter, D J, Agnes Bankier, Apicella, C, Deon J Venter, Andrews, L, Shirley V Hodgson, Sheila A Fisher   +30 more
core   +1 more source

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients [PDF]

, 2022
We evaluated the proportion of BRCA 1/2 germline mutations in Korean patients with sporadic pancreatic ductal adenocarcinoma (PDAC) and its effect on the chemotherapeutic response of FOLFIRINOX. This retrospective study included patients who were treated
Si Young Song, Seung Woo Park, Moon Jae Chung, Jung Hyun Jo, Seungmin Bang, Jeong Youp Park, Hee Seung Lee, Ji Hoon Park, Jae Hee Cho, Sung Ill Jang   +9 more
core   +2 more sources

The Study of BRCA1 and BRCA2 Gene Mutations in Benign and Malignant Lesions of the Breast

Sokoto Journal of Medical Laboratory Science, 2023
Understanding the role of BRCA 1 and BRCA2 gene mutations is critical in the study of breast carcinogenesis. The aim was to study was to investigate BRCA | and BRCA2 gene mutations in benign and malignant lesions of the breast.
Ekundina Victor Olukayode , Unuigbokhai Ayomide Olohigbe , Wilson Serbia Princess
doaj  

Practical consensus recommendation on when to do BRCA testing

South Asian Journal of Cancer, 2018
BRCA-mutation associated breast cancer and to future cancer risks and sensitivity to systemic therapies. Now that rapid genetic testing for BRCA1 and BRCA2 mutations is available, BRCA mutation status can be considered when making treatment and ...
Purvish M Parikh, J Wadhwa, S Minhas, A Gupta, S Mittal, S Ranjan, P Mehta, R Singh, S P Kataria, S Salim, M Ahmed, S Aggarwal   +11 more
doaj   +1 more source